FDA grants approval for first breast cancer drug through 'Real-Time Oncology Review'

[News]

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy.

More... (https://www.news-medical.net/news/20180719/FDA-grants-approval-for-first-breast-cancer-drug-through-Real-Time-Oncology-Review.aspx)